Posted by Michael Wonder on 25 Feb 2026
Siren Biotechnology receives FDA fast track designation for SRN-101 for the treatment of recurrent high grade glioma
24 February 2026 - Siren Biotechnology today announced that the US FDA has granted fast track designation to SRN-101, the Company’s lead AAV-based immuno-gene therapy for recurrent high grade glioma.
Siren recently announced FDA clearance of its first investigational new drug filing for SRN-101, enabling first in human clinical evaluation in patients with recurrent high grade glioma.
